Clinical trial • Phase I • Oncology
Belantamab mafodotin for Relapsed/Refractory multiple myeloma
Phase I trial of Belantamab mafodotin for Relapsed/Refractory multiple myeloma. 27 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Relapsed/Refractory multiple myeloma
- Trial Stage
- Phase I
- Drug Modality
- ADC
Key dates
- Initial CTIS Submission Date
- 25-10-2023
- First CTIS Authorization Date
- 26-01-2024
Trial design
Phase I trial across 2 sites in Greece.
- Target Sample Size
- 27
Eligibility
Recruits 27 Vulnerable population selected (isVulnerablePopulationSelected = true); no further details on consent/assent handling provided in source..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected = true); no further details on consent/assent handling provided in source.
Recruitment
- Planned Sample Size
- 27
- Recruitment Window Months
- 57
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 27
Greece
- Earliest CTIS Part Ii Submission Date
- 01-11-2023
- Latest Decision Or Authorization Date
- 22-01-2026
- Processing Time Days
- 813
- Number Of Sites
- 2
- Number Of Participants
- 9
Sites
- Site Name
- Evangelismos S.A.
- Department Name
- Hematology Clinic
- Principal Investigator Name
- Sosana Dempimpasi
- Principal Investigator Email
- sodeli@yahoo.com
- Contact Person Name
- Sosana Dempimpasi
- Contact Person Email
- sodeli@yahoo.com
- Site Name
- Alexandra Hospital
- Department Name
- Department of Clinical Therapeutics
- Principal Investigator Name
- Meletios - Athanasios Dimopoulos
- Principal Investigator Email
- mdimop@med.uoa.gr
- Contact Person Name
- Meletios - Athanasios Dimopoulos
- Contact Person Email
- mdimop@med.uoa.gr
Sponsor
Primary sponsor
- Full Name
- Glaxosmithkline Research & Development Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- Belantamab mafodotin
- Active Substance
- Belantamab mafodotin
- Modality
- ADC
Related trials
Other published trials that may interest you.
- JNJ-87562761 for Relapsed/Refractory Multiple Myeloma
- Autologous genetically modified T lymphocytes transduced with lentivirus expressing CAR protein directed against BCMA for Relapsed/refractory multiple myeloma
- MEZIGDOMIDE for Relapsed/refractory multiple myeloma
- BELANTAMAB MAFODOTIN for Relapsed/refractory multiple myeloma
- REGN17372 for Relapsed/refractory multiple myeloma